Skip to content

MDMA for anxiety: all studies

Page 6 of 9: studies 51 to 60 of 82, newest first. Back to the MDMA for anxiety overview

Research

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study

Scientific Reports November 24, 2020 Julane Andries, Lisa Jerome, Evan Sola et al. 170 citations

Abstract The success of modern medicine creates a growing population of those suffering from life-threatening illnesses (LTI) who often experience anxiety, depression, and existential distress. We present a novel approach; investigating MDMA-assisted psychotherapy for the treatment of anxiety in people with an LTI. Participants with anxiety from an LTI were randomized in a double-blind study to...

A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Journal of the Neurological Sciences January 31, 2020 Tingying Chi, Jessica A. Gold 95 citations

Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to...

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7

MDMA and Pavlovian Fear Memory: Dose‐Effect Analysis

The FASEB Journal April 1, 2019 Madeline M. Pantoni, Stephan G Anagnostaras

±3,4‐methylenedioxymethamphetamine (MDMA) is a recreational drug that is also being pursued as a therapeutic for PTSD and other mood and anxiety disorders. Despite strong evidence of its therapeutic potential, these pursuits are hindered by evidence that MDMA produces robust neurotoxicity and cognitive deficits at high doses. These findings, however, may not generalize to typical recreational...

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.

Psychopharmacology November 1, 2018 Alicia Danforth, Charles S. Grob, Christopher M Struble et al. 284 citations

Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. To explore feasibility and safety of MDMA-assisted psychotherapy for reduction of social fear and avoidance...

DOI: 10.1007/s00213-018-5010-9 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Asperger’s Social anxiety MDMA-Assisted Psychotherapy: 3 +2

Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter

Scientific Reports January 12, 2018 Kim P. C. Kuypers, Rafael de la Torre, Magı́ Farré et al. 12 citations

Abstract MDMA exerts its main effects via the serotonergic system and the serotonin transporter. The gene coding for this transporter determines the expression rate of the transporter. Previously it was shown that healthy individuals with the short allelic variant (‘ s -group’) of the 5-HTTLPR-polymorphism displayed more anxiety and negative mood, and had a lower transcriptional efficiency...

Anxiety and depression symptoms in Brazilian sexual minority ecstasy and LSD users

Trends in Psychiatry and Psychotherapy November 11, 2017 Lysa Remy, Juliana Nichterwitz Scherer, Luciano Santos Pinto Guimarães et al. 12 citations

Abstract Background This study examined drug use patterns and psychiatric symptoms of anxiety and depression among young Brazilian sexual minority ecstasy and LSD users and compared findings with those reported for their heterosexual peers. Method This cross-sectional study employed targeted sampling and ethnographic mapping approaches via face-to-face interviews conducted at bars and...

MDMA does not alter responses to the Trier Social Stress Test in humans

Psychopharmacology July 1, 2017 Anya K. Bershad, Melissa A. Miller, Harriet de Wit 12 citations

Rationale ±3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a stimulant-psychedelic drug with unique social effects. It may dampen reactivity to negative social stimuli such as social threat and rejection. Perhaps because of these effects, MDMA has shown promise as a treatment for post-traumatic stress disorder (PTSD). However, the effect of single doses of MDMA on responses to an acute...

Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse

Fortschritte der Neurologie · Psychiatrie July 1, 2017 Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al. 10 citations

Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entaktogenen wie 3,4-Methylendioxymethamphetamin (MDMA) im Rahmen von Psychotherapie ist in den letzten Jahren wieder zunehmend ins Licht des wissenschaftlichen Interesses gerückt. Die vorliegende Arbeit fasst die aktuelle Evidenz zur substanzunterstützten...